- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic plaque psoriasis
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 688KB)
Bimekizumab – March 2023
Bimekizumab: Injection 160 mg in 1 mL single use pre-filled syringe, Injection 160 mg in 1 mL single use pre-filled pen; Bimzelx®
Last updated
30 June 2023